The three-year Arizona Biomedical Research Commission Awards will fund research relating to neuropathic and cancer pain, migraines, opioids, antibiotics, antivirals, sinusitis, obesity, diabetes, Parkinson’s disease, pulmonary disease and pediatric acute-onset neuropsychiatric syndrome.Continue reading
Author Archive: AZBio
Enzyme’s movement may be key to new cancer drugs
Interfering with the motion of a kinase enzyme might be a new approach for the development of anti-cancer drugsContinue reading
Brain Tumor Atlas Published in the Journal Science
Researchers around the world use publicly available Ivy Glioblastoma Atlas Project to investigate aggressive brain cancer
AZ-HCIF Featured in AZ Business Magazine
AZBio, OTEF, and the Healthcare Impact Foundation’s efforts to establish an endowment to support the commercialization of life science innovation in Arizona is featured in the May/June issue of AZ Business Magazine.Continue reading
Regenesis Biomedical Announces Initiation of a Clinical Trial on Subjects with Painful Diabetic Distal Symmetric Peripheral Neuropathy (DSPN)
Regenesis Biomedical, a Scottsdale-based medical device company, has initiated a multi-center, randomized clinical trial assessing the Provant® Therapy System for relieving symptoms of painful diabetic distal symmetric peripheral neuropathy (DSPN).Continue reading
Operating on brain gliomas by detecting the ‘glow’
Research by Barrow Neurological Institute physicians and University of Washington scientists on novel imaging technology for malignant brain tumors was published in the April issue of World Neurosurgery.Continue reading
World-renowned heart surgeon joins Banner Health
Banner Health has announced Francisco Arabia, MD, an internationally recognized surgeon and executive leader in thoracic, cardiothoracic vascular and transplant surgery, has joined the organization.Continue reading
TGen develops quality-control test for detecting cancer in blood
Rapid, non-invasive diagnosis assisted by TGen assay could be used to help detect many types of cancerContinue reading
ASU-UA-TGEN Startup Iluminos Licenses Treatment for Alzheimer’s Disease
Iluminos Therapeutics has licensed new compounds designed to treat neurodegenerative diseases, particularly Alzheimer’s. Travis Dunckley, PhD, Assistant Research Professor at the ASU-Banner Neurodegenerative Disease Research Center helped develop the new therapies with lead inventor, Christopher Hulme, PhD, Professor of Medicinal Chemistry in the UA Department of Pharmacy and Toxicology (formerly at Eli Lilly and Amgen) and Arthur Shaw, post-doctoral research fellow at the time. The compounds were designed and synthesized at the University of Arizona (UA) College of Pharmacy, in collaboration with the Translational Genomics Research Institute (TGEN).Continue reading